No Data
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Jiangsu Aidea Pharmaceutical Gets Clinical Trial Approval for AD108 Injection
Jiangsu Aidea Pharmaceutical (688488.SH): AD108 injection has received the drug clinical trial approval notice.
On March 13, 2023, Gelonghui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that the company and its holding subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., received the "Notice of Drug Clinical Trial Approval" (referred to as the "Notice") issued by the National Medical Products Administration on March 12, 2025, approving the company to conduct Phase I clinical trials of the 2.2 class modified new drug AD108 injection. AD108 injection is a modified new drug (Chemical Drug class 2.2), with the active ingredient being human prorenin enzyme, specifically tissue type kallikrein-1 (KLK-1), which is a serine protease secreted by the kidneys.
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Looks Just Right With A 28% Price Jump
Eddy Pharmaceuticals 2024 Annual Results Express Announcement
What Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 27% Share Price Gain Is Not Telling You